EF
BDTX icon

Empowered Funds’s Black Diamond Therapeutics BDTX Stock Holding History

Empowered Funds’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$459K Buy
248,134
+17,957
+8% +$43.9K ﹤0.01% 1703
2026
Q1 		$490K Buy
+230,177
New +$547K ﹤0.01% 1653

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Empowered Funds's BDTX Position: Q2 2026 in Review

Empowered Funds increased its Black Diamond Therapeutics (BDTX) stake by 7.8% in Q2 2026, buying an estimated $43.9K and bringing the position to 248,134 shares worth $459K. The position accounts for ﹤0.01% of the portfolio, ranked #1703.

Empowered Funds first reported a position in BDTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $490K in Q1 2026. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Empowered Funds held 248,134 shares of Black Diamond Therapeutics worth $459K as of Q2 2026.
  • Empowered Funds bought 17,957 Black Diamond Therapeutics shares in Q2 2026, an estimated $43.9K.
  • Black Diamond Therapeutics made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #1703 holding.
  • Empowered Funds first reported a position in Black Diamond Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Empowered Funds's Black Diamond Therapeutics position peaked at $490K in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.